Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Exchange Rate Effect (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Exchange Rate Effect for 3 consecutive years, with -$60000.0 as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect rose 99.24% to -$60000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2025, up 287.58% year-over-year, with the annual reading at $12.8 million for FY2025, 287.58% up from the prior year.
  • Exchange Rate Effect hit -$60000.0 in Q4 2025 for NewAmsterdam Pharma, down from $222000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $8.8 million in Q2 2025 to a low of -$7.9 million in Q4 2024.
  • Historically, Exchange Rate Effect has averaged $917416.7 across 3 years, with a median of $81000.0 in 2025.
  • Biggest five-year swings in Exchange Rate Effect: tumbled 252.05% in 2024 and later surged 1070.96% in 2025.
  • Year by year, Exchange Rate Effect stood at $5.2 million in 2023, then crashed by 252.05% to -$7.9 million in 2024, then soared by 99.24% to -$60000.0 in 2025.
  • Business Quant data shows Exchange Rate Effect for NAMS at -$60000.0 in Q4 2025, $222000.0 in Q3 2025, and $8.8 million in Q2 2025.